Systematic study on expression and prognosis of E2Fs in human colorectal cancer

被引:1
作者
Ma, Yating [1 ,2 ]
Wang, Shijian [2 ]
Bao, Jinfeng [1 ]
Wang, Chengbin [1 ,2 ]
机构
[1] Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Clin Lab, Beijing 100853, Peoples R China
[2] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China
关键词
E2Fs; Colorectal cancer biomarkers; Bio-informatic analysis; Mutation; GENE-EXPRESSION; CELL-CYCLE; PROLIFERATION; BIOMARKERS; TUMORS;
D O I
10.1007/s10147-021-02051-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background E2Fs are important components of transcription factors and play key roles in occurrence or advancement of various cancers, but the expression and exact roles of each E2F in colorectal cancer (CRC) are rarely known. Methods To address this issue, we investigated the roles and prognostic values of E2Fs expressions in CRC patients by searching ONCOMINE, cBioPortal, GEPIA, Matascape and UALCAN. Results E2F1, 3-8 were upregulated at the mRNA level and E2F2 was less expressed in CRC tissues than in normal tissues. The eight E2Fs were correlated with tumor stages of CRC. Survival analysis using GEPIA revealed that high expressions of E2F3, 4 were related with short overall survival in all CRC patients. The mutation rate of E2Fs (60%) was high and genetic alteration in E2Fs was linked with longer overall survival in CRC patients. Functional analysis implied that E2Fs and their 50 nearby genes were concentrated in tumor-related pathways. Conclusions E2Fs may be candidate biomarkers for CRC diagnosis and E2F3, 4 are potential prognosis biomarkers of CRC. Nevertheless, our findings must be validated in the future to popularize the clinical application of E2Fs in CRC.
引用
收藏
页码:362 / 372
页数:11
相关论文
共 32 条
[1]   UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses [J].
Chandrashekar, Darshan S. ;
Bashel, Bhuwan ;
Balasubramanya, Sai Akshaya Hodigere ;
Creighton, Chad J. ;
Ponce-Rodriguez, Israel ;
Chakravarthi, Balabhadrapatruni V. S. K. ;
Varambally, Sooryanarayana .
NEOPLASIA, 2017, 19 (08) :649-658
[2]  
Chang SW, 2015, INT J CLIN EXP PATHO, V8, P12853
[3]   Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges [J].
Das, Vishal ;
Kalita, Jatin ;
Pal, Mintu .
BIOMEDICINE & PHARMACOTHERAPY, 2017, 87 :8-19
[4]   Colorectal cancer [J].
Dekker, Evelien ;
Tanis, Pieter J. ;
Vleugels, Jasper L. A. ;
Kasi, Pashtoon M. ;
Wallace, Michael B. .
LANCET, 2019, 394 (10207) :1467-1480
[5]  
Fang ZJ, 2019, AM J CANCER RES, V9, P2679
[6]   Mutated KRAS Results in Overexpression of DUSP4, a MAP-Kinase Phosphatase, and SMYD3, a Histone Methyltransferase, in Rectal Carcinomas [J].
Gaedcke, Jochen ;
Grade, Marian ;
Jung, Klaus ;
Camps, Jordi ;
Jo, Peter ;
Emons, Georg ;
Gehoff, Anastasia ;
Sax, Ulrich ;
Schirmer, Markus ;
Becker, Heinz ;
Beissbarth, Tim ;
Ried, Thomas ;
Ghadimi, B. Michael .
GENES CHROMOSOMES & CANCER, 2010, 49 (11) :1024-1034
[7]   Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal [J].
Gao, Jianjiong ;
Aksoy, Buelent Arman ;
Dogrusoz, Ugur ;
Dresdner, Gideon ;
Gross, Benjamin ;
Sumer, S. Onur ;
Sun, Yichao ;
Jacobsen, Anders ;
Sinha, Rileen ;
Larsson, Erik ;
Cerami, Ethan ;
Sander, Chris ;
Schultz, Nikolaus .
SCIENCE SIGNALING, 2013, 6 (269) :pl1
[8]   E2F4 Expression Is Required for Cell Cycle Progression of Normal Intestinal Crypt Cells and Colorectal Cancer Cells [J].
Garneau, Hugo ;
Paquin, Marie-Christine ;
Carrier, Julie C. ;
Rivard, Nathalie .
JOURNAL OF CELLULAR PHYSIOLOGY, 2009, 221 (02) :350-358
[9]  
Guo Ai Ye, 2017, Asian Pac J Cancer Prev, V18, P271
[10]   A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics [J].
Hong, Yi ;
Downey, Thomas ;
Eu, Kong Weng ;
Koh, Poh Koon ;
Cheah, Peh Yean .
CLINICAL & EXPERIMENTAL METASTASIS, 2010, 27 (02) :83-90